Data Validate Effectiveness of both NewCardio Products CardioBip™ and my3KG™ to Diagnose Acute Cardiac Events
SANTA CLARA, Calif., June 16, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that two of its recent medical and technical submissions have been accepted for their presentations at the 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society conference.
The two papers: 'Wireless Monitoring of Reconstructed 12-Lead ECG in Atrial Fibrillation Patients Enables Differential Diagnosis of Recurrent Arrhythmias' and 'Algorithm for Quantitative 3-Dimensional Analysis of ECG Signals Improves Myocardial Diagnosis Over Cardiologists in Diabetic Patients', will be presented during the conference to be held September 1-4, in Boston, Mass.
NewCardio scientists and their academic medical collaborators will present data from recently completed clinical studies that highlight the diagnostic potentials of two company products, CardioBip™ and my3KG™:
- The first of these studies showed that CardioBip accurately captured, wirelessly transmitted, and reconstructed full 12-lead ECG data from patients with atrial fibrillation (AF) who had previously undergone a therapeutic catheter ablation procedure. Such patients are at significant risk for stroke from recurrent bouts of AF; moreover, currently available cardiac monitoring techniques all have significant limitations for recurrent AF detection that may be addressed by long-term CardioBip monitoring. The NewCardio-sponsored study showed that (1) post-ablation AF patients could conveniently monitor themselves for recurrent AF with CardioBip for the entire duration of the study (6 months); (2) CardioBip frequently detected AF recurrences, whether the patient had symptoms or not; and (3) CardioBip was substantially more sensitive and accurate that periodic sustained (12-lead 24 hours Holter) monitoring in detecting recurrent AF.
- The second study showed that my3KG was substantially more sensitive and accurate than the standard 12-lead electrocardiogram in diagnosing acute heart attack (myocardial infarction, or MI) in patients with Type II diabetes mellitus (Type II DM). This is a significant and important advance because Type II DM is a large and growing patient population with a high risk of MI, and a population in which an accurate MI diagnosis is notoriously difficult to obtain.
"This now marks the third consecutive year this prestigious medical conference has accepted two of our papers for presentation," said Dorin Panescu, Ph.D., Chief Technical Officer of NewCardio and a Fellow of the IEEE. "The acceptance of these submissions reflects the growing recognition of the quality and innovative nature of our science and technology, and that they meet important and previously unmet medical needs."
The conference program will consist of plenary lectures, symposia, workshops and invited sessions of the latest significant findings and developments in all the major fields of biomedical engineering. Submitted papers were peer reviewed. The NewCardio studies will be presented in oral sessions at the IEEE meeting, and will appear in the Conference Proceedings, which are indexed in PubMed/MEDLINE.
About the IEEE
IEEE is the world's largest professional association dedicated to advancing technological innovation and excellence for the benefit of humanity. IEEE and its members inspire a global community through IEEE's highly cited publications, conferences, technology standards, and professional and educational activities. IEEE's core purpose is to foster technological innovation and excellence for the benefit of humanity.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2010 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Jeff Stanlis, Partner
SOURCE NewCardio, Inc.